PHAR (pharming.com) יחס שווי שוק לשווי בספרים

This chart of the market price for Pharming Group N.V. (PHAR) reflects the performance of a company developing treatments for hereditary angioedema. The lifelong nature of the therapy ensures stable demand, turning the product into a reliable cash cow where the metric stands at 3.29. The business relies on exclusive orphan drug rights and a unique protein synthesis process. However, the concentration on a single drug and the costs associated with new launches create certain financial risks.

The monopoly status of Pharming Group N.V. (PHAR) in the production of proteins for treating orphan diseases creates high added value that exceeds the value of its physical assets. By analyzing changes in the market-to-book ratio, an investor can observe the market premium over the book value of net assets, which allows for an assessment of the premium paid for the company's unique technologies and future cash flows.